Rivaroxaban is under clinical development by Bio-Synectics and currently in Phase I for Deep Vein Thrombosis (DVT). According to GlobalData, Phase I drugs for Deep Vein Thrombosis (DVT) have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Rivaroxaban’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Rivaroxaban is under development for the treatment of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, deep vein thrombosis (DVT), pulmonary embolism and venous thromboembolism. The drug candidate is an incrementally modified drug. It is administered orally in the form of a tablet. The drug candidate is developed based on NUFS (Nanoparticulation Using Fat and Supercritical fluids) technology. The drug candidate acts by targeting factor Xa.
Bio-Synectics is is engaged in the business of nanopharmaceuticals, materials, and drug delivery systems to pharmaceutical industries that specializes in the technology of nanoparticles. It is headquartered in Seoul, Republic of Korea (South Korea).
For a complete picture of Rivaroxaban’s drug-specific PTSR and LoA scores, buy the report here.